Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Hamburg - Delayed Quote EUR

HAEMATO AG (HAEK.HM)

Compare
12.80
0.00
(0.00%)
At close: April 4 at 6:46:40 PM GMT+2
Loading Chart for HAEK.HM
  • Previous Close 12.80
  • Open 0.00
  • Bid --
  • Ask --
  • Day's Range 0.00 - 0.00
  • 52 Week Range 0.00 - 18.75
  • Volume 0
  • Avg. Volume 640
  • Market Cap (intraday) 109.815M
  • Beta (5Y Monthly) 0.16
  • PE Ratio (TTM) 6.92
  • EPS (TTM) 1.85
  • Earnings Date --
  • Forward Dividend & Yield 0.04 (0.31%)
  • Ex-Dividend Date Jul 17, 2024
  • 1y Target Est --

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO brand, and cosmetics under the brand M1 SELECT, as well as supplies third party-products. It serves clinics, pharmacies, wholesalers, and medical test centers. HAEMATO AG was founded in 1993 and is based in Schönefeld, Germany.

www.haemato.ag

76

Full Time Employees

December 31

Fiscal Year Ends

Recent News: HAEK.HM

View More

Performance Overview: HAEK.HM

Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is DAX P (^GDAXI) .

YTD Return

HAEK.HM
3.23%
DAX P (^GDAXI)
3.68%

1-Year Return

HAEK.HM
18.79%
DAX P (^GDAXI)
12.16%

3-Year Return

HAEK.HM
38.61%
DAX P (^GDAXI)
42.18%

5-Year Return

HAEK.HM
3.92%
DAX P (^GDAXI)
116.69%

Compare To: HAEK.HM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HAEK.HM

View More

Valuation Measures

Annual
As of 4/4/2025
  • Market Cap

    66.94M

  • Enterprise Value

    43.62M

  • Trailing P/E

    6.92

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.26

  • Price/Book (mrq)

    0.45

  • Enterprise Value/Revenue

    0.17

  • Enterprise Value/EBITDA

    3.12

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.68%

  • Return on Assets (ttm)

    3.22%

  • Return on Equity (ttm)

    6.52%

  • Revenue (ttm)

    260.81M

  • Net Income Avi to Common (ttm)

    9.61M

  • Diluted EPS (ttm)

    1.85

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.94M

  • Total Debt/Equity (mrq)

    2.07%

  • Levered Free Cash Flow (ttm)

    4.64M

Research Analysis: HAEK.HM

View More

Company Insights: HAEK.HM

Research Reports: HAEK.HM

View More